Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Rangering i aksjer #25843
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Aksjekurs
$0.40861751
Markedsverdi
$45.81M
Endring (1 dag)
-1.15%
Endring (1 år)
-46.41%
Land
TW
Handel TaiRx, Inc. (6580)

Kategori

EPS for TaiRx, Inc. (6580)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til TaiRx, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for TaiRx, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US